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Abstract
Background: Approximately half of all human genes use alternative transcription start sites (TSSs) to control mRNA
levels and broaden the transcriptional output in healthy tissues. Aberrant expression patterns promoting
carcinogenesis, however, may arise from alternative promoter usage.
Results: By profiling 108 colorectal samples using exon arrays, we identified nine genes (TCF12, OSBPL1A, TRAK1,
ANK3, CHEK1, UGP2, LMO7, ACSL5, and SCIN) showing tumor-specific alternative TSS usage in both adenoma and
cancer samples relative to normal mucosa. Analysis of independent exon array data sets corroborated these findings.
Additionally, we confirmed the observed patterns for selected mRNAs using quantitative real-time reverse-
transcription PCR. Interestingly, for some of the genes, the tumor-specific TSS usage was not restricted to colorectal
cancer. A comprehensive survey of the nine genes in lung, bladder, liver, prostate, gastric, and brain cancer revealed
significantly altered mRNA isoform ratios for CHEK1, OSBPL1A, and TCF12 in a subset of these cancer types.
To identify the mechanism responsible for the shift in alternative TSS usage, we antagonized the Wnt-signaling
pathway in DLD1 and Ls174T colorectal cancer cell lines, which remarkably led to a shift in the preferred TSS for
both OSBPL1A and TRAK1. This indicated a regulatory role of the Wnt pathway in selecting TSS, possibly also
involving TP53 and SOX9, as their transcription binding sites were enriched in the promoters of the tumor
preferred isoforms together with their mRNA levels being increased in tumor samples.
Finally, to evaluate the prognostic impact of the altered TSS usage, immunohistochemistry was used to show
deregulation of the total protein levels of both TCF12 and OSBPL1A, corresponding to the mRNA levels observed.
Furthermore, the level of nuclear TCF12 had a significant correlation to progression free survival in a cohort of 248
stage II colorectal cancer samples.
Conclusions: Alternative TSS usage in colorectal adenoma and cancer samples has been shown for nine genes,
and OSBPL1A and TRAK1 were found to be regulated in vitro by Wnt signaling. TCF12 protein expression was
upregulated in cancer samples and correlated with progression free survival.
Background
Colorectal cancer (CRC) is a leading cause of cancer
mortality with more than 600,000 deaths per year glob-
ally [1]. CRC can be divided into two major subgroups:
microsatellite stable (MSS) and microsatellite unstable
cancers (MSI), the latter being characterized by a
defective mismatch repair system, which leads to muta-
tions in microsatellite repeat regions [2]. The two sub-
groups also show differences in transcriptional profiles
and clinical disease course [3]. A key event in the trans-
formation of colonic epithelial cells is the activation of
the Wnt-signaling pathway, which is observed in the vast
majority of colorectal tumors [4]. Following activation of
the Wnt pathway, b-catenin accumulates in the nucleus
where it interacts with members of the TCF/LEF tran-
scription factors, such as TCF1 (gene symbol TCF7)a n d
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target genes including MYC, SOX9 and Cyclin D1.
Furthermore, it has previously been shown that Wnt
signaling also plays a regulatory role in alternative
splicing [5,6].
The generation of proteome diversity from a rather
limited number of genes is primarily due to alternative
splicing and alternative promoter usage, the latter leading
to multiple transcripts from the same gene with different
transcription start sites (TSSs). It has been estimated that
30-50% of all human genes have multiple promoters
[7-9], and among the genes with experimentally well
described alternative promoters are several cancer related
genes such as MYC [10], TP53 [11] and BRCA1 [12].
Genome-wide predictive analysis has shown that alterna-
tive promoters are overrepresented in genes involved in
development and transcriptional control, whereas genes
with only a single promoter are more frequently involved
in general cellular processes [9]. Alternative TSS can
have crucial impact on both the transcriptional level and
stability of the transcript as well as the function and cel-
lular localization of the translated protein [8]. An exam-
ple of a transcript with directly opposite effects is the
transcription factor TCF1 where the use of alternative
promoters results in the formation of two isoforms with
different b-catenin binding capability. While the long iso-
form of TCF1 interacts with b-catenin and stimulates
transcription of Wnt-target genes, the short isoform,
unable to bind b-catenin but with the DNA binding
domain intact, acts as a dominant negative regulator of
b-catenin mediated Wnt signaling [13].
In the present study, a genome-wide search revealed
nine genes with tumor-specific TSS usage in neoplastic
colorectal tissue samples. For some of the genes, the
tumor-specific TSS usage was not restricted to CRC, but
w a so b s e r v e di no t h e rc a n c e rt y p e sa sw e l l .T h eu s eo f
alternative TSSs in OSBPL1A and TRAK1 was found to
be regulated by the Wnt pathway and also observed in
gastric, prostate and brain tumors. Protein levels of OSB-
PL1A and TCF12 were found to be deregulated in color-
ectal tumors and the protein expression of TCF12
correlated with progression free survival of stage II CRC.
Results
Identification of differential transcription start site usage
To investigate whether the use of alternative TSSs was
associated with tumor development, normal colorectal
mucosa (n = 24), colorectal adenoma (n = 49) and CRC
samples (n = 35) were profiled using the Affymetrix
Human Exon 1.0 ST Array. The Refseq database (hg18)
was queried for genes with two or more known tran-
scripts with different TSSs. In total, 2176 protein-coding
genes containing multiple TSSs were identified and
matched to exon array core transcript clusters by gene
symbol of which 2036 genes had available exon expres-
sion data. Genes, containing exons potentially involved in
tumor associated alternative TSS usage or alternative
splicing, were identified using a splicing ANOVA
approach. Additional filtering criteria (see methods) were
used to select 156 candidate genes for manual inspection
in a genomic context. The manual curation indicated
tumor associated alternative TSS usage in nine (TCF12,
OSBPL1A, TRAK1, ANK3, CHEK1, UGP2, LMO7, ACSL5
and SCIN) of the 156 genes. To confirm these findings,
two independent CRC sample sets (covering a total of 18
normal mucosa, six adenomas and 28 CRC samples)
were investigated. All nine genes showed expression pro-
files consistent with tumor-specific alternative TSS usage
in at least one of the independent validation sets.
qRT-PCR validation of alternative TSS candidates
Three candidate genes (TCF12, OSBPL1A and TRAK1)
with different expression characteristics were chosen for
technical validation with quantitative real-time reverse-
transcription PCR (qRT-PCR) on a subset of the samples
used for exon array analysis. Transcription factor 12
(TCF12), a member of the basic helix-loop-helix E-protein
family with an E-box consensus binding site, exists as a
long and a short variant. According to the exon array data,
the long variant was expressed in both normal and tumor
samples at roughly the same level, whereas the short iso-
form was expressed in the majority of the tumor samples,
but not detected above background in the normal samples
(Figure 1A). This indicated that the short isoform of
TCF12 was de novo synthesized in the majority of the
tumor samples, especially in adenomas and MSS carcino-
mas (Figure 1B). Exon array data from paired normal and
adenoma samples were available for 18 patients, and for
five of these patients exon array expression data were
available for a matched carcinoma sample as well.
Increased expression of TCF12 exon 1B in tumor samples
was seen in 21 of 23 sample pairs (p = 0.001) (Additional
file 1A). For qRT-PCR validation of the shift in TCF12
TSS usage, six normal samples, 14 adenoma samples,
divided in two groups based on expression of the short
TCF12 isoform (high or low), and six MSS cancer samples
were selected. qRT-PCR confirmed de novo expression of
the short TCF12 isoform (exon 1B) in many tumor sam-
ples (Figure 1C) and showed strong correlation to the
exon array data (RS = 0.82, Spearman correlation).
Oxysterol-binding protein-related protein 1 (OSBPL1A)
is an intracellular lipid receptor which is a member of the
oxysterol-binding protein (OSBP) family and exists as a
long and a short transcript variant. The long variant was
expressed at roughly the same level in normal and tumor
samples, whereas the short variant was down-regulated in
most tumor samples (Figure 1D). The ratio between the
long and short variant was shifted significantly towards
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Page 2 of 14the long variant in both adenoma and cancer samples (Fig-
ure 1E). This shift was also highly significant (p = 7 × 10
-
10) in the 23 paired normal and tumor samples, where a
lower ratio was observed in all 23 tumor samples (Addi-
tional file 1B). This tumor-specific isoform shift was con-
firmed by qRT-PCR in 53 tissue samples (13 normal, 18
adenomas and 22 MSS cancers) (Figure 1F), which showed
a robust correlation between exon array and qRT-PCR
data (RS = 0.52, Spearman correlation).
Finally, Trafficking kinesin-binding protein 1 (TRAK1), a
kinesin-binding protein associated with mitochondria,
contains two alternative start exons (exon 1A and 1B)
with differential expression in normal and tumor samples
(Figure 1G). The ratio was shifted towards exon 1B in
both adenoma and cancer samples (Figure 1H), including
all 23 tumors with matched normal samples (p = 5 × 10
-8)
(Additional file 1C). This trend was also confirmed by
qRT-PCR in the same 53 tissue samples described above
( F i g u r e1 I ) .A g a i n ,af i n ec o r r e l a t i o nb e t w e e ne x o na r r a y
and qRT-PCR data was observed (RS = 0.58). We specu-
lated whether alternative splicing rather than alternative
TSS could explain the observed findings for TRAK1.H o w -
ever, in both normal and tumor samples only one qRT-
PCR product was observed for the primer set spanning
the alternative TRAK1 exon 1B (from exon 2 to 3), with a
length consistent with lack of exon 1B. This demonstrates
that no transcript containing exons 2, 1B and 3 exists. By
contrast PCR with primers in exon 1B and 3 produces a
product. This indicates that the transcript template of the
latter product starts with exon 1B, and, hence, that
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Figure 1 Expression of TCF12, OSBPL1A and TRAK1 isoforms in colorectal neoplasia. A, Exon structure and exon array expression of TCF12
in normal mucosa (n = 24) and tumor (n = 84) samples. Error bars represent SE. B, Exon array expression levels of the alternative start exon (1B)
in mucosa samples, adenomas, and carcinomas (MSS and MSI). C, qRT-PCR validation of exon 1B expression, primer position is indicated in A. D,
Exon structure and exon array expression of OSBPL1A as in A. E, Exon array isoform ratio of OSBPL1A as in B. F, qRT-PCR validation of OSBPL1A
isoform ratio. G, Exon structure and exon array expression of TRAK1 as in A. H, Exon array isoform ratio of TRAK1 as in B. I, qRT-PCR validation of
TRAK1 isoform ratio. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.
Thorsen et al. BMC Genomics 2011, 12:505
http://www.biomedcentral.com/1471-2164/12/505
Page 3 of 14alternative TSS rather than alternative splicing is the
mechanism generating the transcript. In conclusion, qRT-
PCR confirmed the tumor associated alternative TSSs for
all three candidates, demonstrating that exon array data
reliably identify alternative TSS usage.
qRT-PCR validation of alternative TSS in laser capture
microdissected samples
It is well known that tissue composition changes from
normal mucosa to tumor biopsies, and, potentially, the
observed changes in TSS usage could reflect this rather
than altered expression in the neoplastic cells. To address
this question, we analyzed TCF12, OSBPL1A and TRAK1
isoform expression in laser capture microdissected (LCM)
samples from six patients. From each patient, tumor and
adjacent normal tissue biopsies were dissected to provide
four samples per patient (normal epithelial cells, stroma
from normal biopsies, CRC cells and cancer derived
stroma). The short TCF12 isoform was expressed in half
of the patients, and solely in cancer cells or, interestingly,
cancer derived stroma, thus, confirming the tumor-specifi-
city we observed in non-LCM samples (Additional file
2A). For OSBPL1A, a primer set measuring the long
variant showed expression in half of the cancer and the
cancer derived stroma samples, whereas the expression in
the normal epithelium was low in all but one sample. A
primer set measuring the expression of both isoforms
showed low expression levels in both cancer epithelium
and cancer derived stroma, whereas four of the six patients
had a markedly higher expression in the normal epithe-
lium and, for the same samples, a lower expression in the
stroma from normal biopsies (Additional file 2B). TRAK1
exon 1A was found to be expressed in only two normal
epithelial samples, whereas no expression of the tumor
preferred exon 1B was observed in either fraction from the
normal sample. Exon 1B was expressed in half of the can-
cer epithelium samples of which two also had expression
of exon 1A (Additional file 2C). In summary, the experi-
ments confirmed that the tumor associated alternative
TSS usages observed for TCF12, OSBPL1A and TRAK1
were indeed due to altered expression in the carcinoma
cells, and not a consequence of altered tissue composition.
Alternative TSS use in other cancer types
Because many of the cancer associated expression changes
identified to date generally play a role in cancers from dif-
ferent organs, we speculated whether the collection of
tumor associated alternative TSSs identified here in the
context of CRC could also have relevance to other cancers.
To address this question, we acquired exon array expres-
sion data from gastric, liver, lung, bladder, brain and pros-
tate normal and cancer samples. CHEK1 tumor associated
alternative TSSs usage, which yields transcripts differing
only in their 5’ untranslated region (UTR) (Figure 2A),
was most widely associated with cancer. In addition to
CRC, a significant change in TSS usage was found in gas-
tric, liver, lung and bladder cancer along with brain glio-
mas (Figure 2B-G). Significant expression changes of the
OSBPL1A isoforms were observed in gastric and prostate
cancer and metastases from prostate cancer patients along
with brain gliomas (Additional file 3A-C). For liver, lung
and bladder cancer, the trend was the same although not
significant (Additional file 3D-F). Isoform expression
changes were also found for TCF12 in brain gliomas
(Additional file 3G). In summary, the analysis confirmed
that some of the observed tumor associated TSS usages
were not restricted to CRC.
Transcription factor binding analysis
Differences in preferred TSS could be explained by differ-
ential expression of transcription factors (TFs) controlling
the activation of promoters located near the TSS of the
nine selected genes. To identify TFs potentially responsible
for the observed shifts in expressed isoforms, we per-
formed TF binding site enrichment analysis in the TOU-
CAN2 software [14]. We chose to look at the sequence
300 bp upstream and 100 bp downstream from the TSS,
which was defined as the start site of the matching Refseq
sequence. Significantly overrepresented TF binding
matrices were queried against the exon array expression
data to identify deregulated TFs with enriched binding.
Five TFs were significantly downregulated in tumor sam-
ples (p < 0.05, Benjamini-Hochberg corrected) and had
enriched binding motifs near the TSS most commonly
used in the normal mucosa samples (MEIS1, NR3C1,
HNF4, IKZF3 and FOXO1), whereas only two TFs, TP53
and SOX9, were found to be significantly upregulated in
tumor samples (p < 0.05, Benjamini-Hochberg corrected)
along with having binding enrichment near the preferred
TSS of the carcinoma samples, and, interestingly, SOX9 is
known to be regulated by the Wnt pathway [15]. In sum-
mary, tumor-specific TF deregulation may contribute to
the observed change of TSS usage.
The Wnt pathway regulates the expression of OSBPL1A
isoforms
TCF4 is a key mediator of the Wnt-signaling pathway
which is mutationally activated in ~85% of CRCs [4]. Pre-
viously, in vivo TCF4 binding domains have been identi-
fied in the Ls174T CRC cell line using a ChIP-on-chip
approach [16]. Interestingly, this study indicated that
TCF4 binds just upstream of the TSS of the long OSB-
PL1A variant as well as upstream of both TRAK1 TSSs.
This suggests that TCF4 is involved in regulating the TSS
usage of these genes. To determine the impact of altered
Wnt signaling (TCF4 activity) on the expression of OSB-
PL1A and TRAK1 isoforms, overexpression of a dominant
negative form of TCF4 (dnTCF4) was used to interrupt
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Page 4 of 14the TCF4 mediated part of the Wnt-pathway in the two
CRC cell lines, DLD1 and Ls174T [17]. The ratio between
the long and the short isoform of OSBPL1A was signifi-
cantly changed in both the DLD1 (p = 6.5 × 10
-4) and the
Ls174T (p = 5 × 10
-6) cell lines when dnTCF4 was overex-
pressed (Figure 3A), mainly due to downregulation of the
long variant. Interestingly, overexpression of a dominant
negative form of TCF1, another transcription factor
involved in mediating Wnt signaling, did not alter the
ratio between the two OSBPL1A isoforms (Figure 3A).
Although dnTCF4 targets the same sequence elements as
TCF4, it cannot be ruled out that the observed expression
changes could be unexpected artifacts of the dnTCF4
overexpression rather than disrupted Wnt-signaling. To
address this caveat, we antagonized the signaling cascade
upstream of TCF4 (in DLD1 cells) by siRNA mediated
knock down of b-catenin, the key regulator of Wnt signal-
ing. As for the dnTCF4 overexpression experiment, this
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Figure 2 CHEK1 isoform expression in colorectal and other cancers. A, Exon structure and exon array expression of CHEK1 in normal
colorectal mucosa (n = 24) and colorectal tumor (n = 84) samples. Error bars represent SE. B, Exon array isoform ratio of CHEK1 in normal
colorectal mucosa samples, adenomas, and carcinomas (MSS and MSI), C, expression in normal gastric and gastric cancer samples, D, expression
in liver normal and cancer, E, expression in lung normal and cancer F, expression in bladder normal and cancer and, G, expression in normal
brain and brain gliomas. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.
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Page 5 of 14led to a significant change (p = 2.9 × 10
-5)i nt h er a t i o
between the two OSBPL1A isoforms (with the same direc-
tion and magnitude, Figure 3B). This indicated that the
Wnt pathway is truly involved in regulating the TSS usage
of OSBPL1A.
For TRAK1, the ratio between the two isoforms
shifted significantly, either when dnTCF1 or dnTCF4
was overexpressed (Figure 3C). Surprisingly, the most
frequently found isoform in normal mucosa samples
was the most infrequent when the Wnt-pathway was
disrupted by the overexpression of dnTCF1 or dnTCF4.
No change in the isoform ratio was seen when b-catenin
was downregulated by siRNA (Figure 3D), implying that
t h ec h a n g ei nTRAK1 ratio observed was executed in a
b-catenin independent manner.
Immunohistochemical staining of TCF12 and OSBPL1A in
matched normal and tumor tissues
To address whether the change in mRNA isoforms had
impact on protein expression, immunohistochemical
(IHC) analysis of TCF12 was performed on a tissue micro-
array (TMA) containing 50 normal mucosa and 51
matched adenocarcinoma samples with an antibody speci-
fic for an epitope present in both the long and short var-
iant. The IHC revealed a significant increase in both the
nuclear staining (p < 0.001, Fishers exact test) and in the
percentage of stained cell (p <0.001, Fishers exact test) in
cancer compared to normal samples (Figure 4A). This
could be explained by the de novo synthesis of the short
TCF12 isoform in a subset of cancers, as the mRNA
encoding the long variant was expressed at equivalent
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Figure 3 Wnt signaling regulates isoform expression of OSBPL1A and TRAK1.A ,OSBPL1A isoform ratio measured by qRT-PCR in DLD1 and
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Page 6 of 14levels in normal and cancer samples. However, this may
also reflect other different properties such as a difference
in stability of the two isoforms. We observed only very few
stained cells in the cancer stroma, corresponding to the
weak expression of the short TCF12 mRNA isoform
detected in LCM tumor stroma samples.
OSBPL1A IHC staining was performed on the TMA
described above with an antibody targeting a peptide
found in both transcript variants. This showed a signifi-
cantly higher cytoplasmic staining intensity in normal
epithelium compared to cancer cells (p < 0.001, Fishers
exact test), whereas no difference in the percentage of
stained cells was observed due to the pervasive expres-
sion of OSBPL1A in both normal and cancer tissue (Fig-
ure 4B). This was in agreement with our mRNA
expression levels as the short OSBPL1A variant is down-
regulated in cancer samples, whereas the long OSBPL1A
variant was expressed at similar levels in the normal and
tumor samples.
TCF12 protein expression is associated with recurrence-
free survival
To investigate the association between recurrence-free
survival and TCF12 or OSBPL1A expression, we used a
TMA containing biopsies from 268 stage II adenocarcino-
mas. Both the intensity of TCF12 and OSBPL1A and the
percentage of stained cells were tested for association to
recurrence-free survival. A very good inter-observer agree-
ment was seen for all tested IHCs (kappa scores ranging
from 0.74-0.83), and we found that TCF12 staining inten-
sity was significantly associated with progression-free
survival (log rank test p = 0.037) when data was dichoto-
mized with the respect to strong intensity samples versus
negative/weak/moderate intensity samples. Kaplan-Meier
curves for TCF12 staining intensity (Figure 5) showed an
increased recurrence rate for patients with biopsies that
have a strong TCF12 staining. No significant association
to recurrence-free survival was observed for the two OSB-
PL1A IHC staining parameters or the percentage of cells
positive for TCF12. Univariate Cox regression analysis was
implemented to examine the influence of each of the clini-
cal parameters on progression-free survival, and we found
TCF12 nuclear intensity to be significant (p = 0.04)(Table
1). Finally, multivariate analysis was performed including
TCF12 nuclear intensity and the number of lymph nodes
examined, and we found TCF12 nuclear intensity to be
independently associated with progression-free survival
(Table 1).
In silico protein predictions
The potential structural and functional differences
between the differentially expressed isoforms were ana-
lyzed using various in silico protein function and struc-
ture prediction tools, regulatory elements in untranslated
regions (UTR) prediction tools along with already
reported experimental data [18-24]. The results are sum-
marized in Table 2, where the number of amino acids
unique to the long or short variants is listed along with
which protein domains are encoded by the unique amino
acids, the presence of leader peptides and 5’UTR
domains. Notably, significant functional differences are
predicted between the long or short isoforms of TCF12,
OSBPL1A, TRAK1, CHEK1, ANK3, LMO7 and SCIN
indicating that the observed tumor associated changes in
TSS usage probably have an impact on the growth prop-
erties of the neoplastic cells.
A
B
    Normal epithilial cells    Carcinoma cells
    Normal epithilial cells    Carcinoma cells
Figure 4 TCF12 and OSBPL1A expression detected by
immunohistochemistry. A, TCF12 expression detected by IHC in
normal epithelial cells and adenocarcinoma cells. B, OSBPL1A
expression detected by immunohistochemistry in normal epithelial
cells and adenocarcinoma cells. All images are × 10.
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This study reports the results of a genome-wide screen-
ing for alternative TSS usage between normal and neo-
plastic colorectal samples. In total, we identified nine
genes with alternative TSS usage and validated them in
an independent cohort. A subset of the candidates was
validated by qRT-PCR on the RNA used for array analy-
sis and on RNA from LCM samples. TF binding analysis
suggested that p53 and SOX9 might be responsible for
a l t e r i n gt h eT S Su s ea st h e ya r eb o t hu p r e g u l a t e di n
cancer and have enriched binding sites in the promoters
associated with the TSS preferred by the neoplastic
cells. Disruption of Wnt signaling using two different
CRC cell lines further showed that perturbed Wnt-sig-
naling may also play a role in regulating alternative TSS
usage of OSBPL1A and TRAK1,m a y b et h r o u g hS O X 9
which is known to be a Wnt-regulated TF [15].
The vast majority of scientific reports commonly refer to
individual genes as one entity encoding a predominant
transcript. This is a drastic oversimplification considering
that experimental evidence supports the existence of at
least two functional promoters for > 50% of all genes
[25,26], and, furthermore, it has the unfortunate conse-
quence that potentially important transcriptional variants
may be ignored. Such transcript diversity is generated by
various mechanisms such as alternative splicing, alterna-
tive TSS usage and alternative polyadenylation usage,
which generate families of transcripts from a single gene
locus. Additionally, the use of DNA methylation appears
to contribute to differential usage of alternative promoters
in multiple tissue types [27] as well as in cancer [28]. We
have previously detected cancer specific alternative
splicing in colorectal, prostate and bladder cancer [29],
and also shown that disruption of Wnt signaling can
change the splicing pattern in colorectal, lung and gastric
cancer [6]. The findings in this paper extend these pre-
vious observations by providing specific examples of tran-
script isoforms that arise through tumor-specific
alternative TSS usage that occur not only in colorectal,
b u ta l s oi naw i d er a n g eo fo t h e rc a n c e r s .W eh a v en o t
addressed potential alternative splicing of TCF12, OSB-
PLA1 and TRAK1 in this study, but have shown that the
exon expression pattern and qPCR validation is consistent
with alternative TSS. In TCF12 and OSBPL1A, the expres-
sion follows the pattern of already described short and
long transcript isoforms, and for alternative splicing to
explain this pattern, novel extreme 5’ start exons would
have to be included in the transcript of both genes fol-
lowed by alternative splicing of at least eight otherwise
constituve spliced exons, a scenario we consider highly
unlikely.
For the transcriptional changes to impact tumor cell
growth, it is crucial that they translate into protein
changes. We used two different strategies to address this
issue. First, IHC analysis showed a significant difference in
the total protein level of TCF12 and OSBPL1A between
normal and cancer samples consistent with the mRNA
expression pattern we observed. Furthermore, we found a
correlation between the total TCF12 protein expression
level and progression free survival. We did not perform
IHC analysis of TRAK1 as a recent study already reported
that elevated levels of TRAK1 are associated with poor
prognosis in CRC patients [30]. Second, in silico analysis
was used to predict the impact of an altered TSS on
At risk:
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Figure 5 Kaplan-Meier curves for recurrence-free survival according to TCF12 staining intensity. IHC staining intensity of TCF12 on a
colorectal stage II TMA was used to generate Kaplan-Meier curves for recurrence free survival. Intensity scores were divided in negative/weak/
moderate versus strong staining intensity. The log-rank test was used to generate the p-value by comparing the survival curves. Number at risk
are listed below the plot and censored samples are indicated with a vertical bar.
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Page 8 of 14Table 1 Univariate and multivariate Cox regression analysis for progression free survival
Univariate analysis Multivariate analysis
Factor Patients (n = 248) HR 95% CI p-val HR 95% CI p-val
TCF12 expression
Neg/weak 200 1 Reference 1 Reference
Strong 48 2.03 1.03-4.01 0.04 2.24 1.17-4.73 0.02
Sex
Female 120 1 Reference
Male 128 1.82 0.95-3.51 0.07
Age at surgery
< = 71 128 1 Reference
>71 120 1.26 0.67-2.38 0.46
Tumour location
Colon 158 1 Reference
Rectum 90 1.11 0.57-2.08 0.80
T-stage
pT3 226 1 Reference
pT4 22 0.81 0.27-2.80 0.74
Tumor size
a
<50 mm 135 1 Reference
>50 mm 112 0.70 0.35-1.30 0.24
Histological type
a
Adenocarcinoma 217 1 Reference
Mucinous 27 1.18 0.46-4.88 0.50
Number of nodes
a
< = 10 119 1 Reference 1 Reference
>10 119 2.01 1.00-4.04 0.05 2.10 1.00-4.03 0.05
HR = hazard ratio; 95% CI = 95% confidence interval.
aPatients with missing values were excluded from the analysis.
Table 2 Protein and 5’ UTR in silico predictions
Unique AA
a Protein domains Signal peptide Glucosylation and phosphorylation 5’UTR
Gene Long Short Long Short Long Short Long Short Long Short
TCF12 193 23 Yes Yes 10 glyco, 27 phos
OSBPL1A 513 3 Ank
b,Pleck
c No No 31 phos
TRAK1 96 38 Yes No
CHEK1 0 No No uORF
d
ANK3 872 6 20 Ank
b No No 3 glyco, 33 phos
UGP2 11 No No uORF
d
LMO7 285 Calponin Yes No 21 phos IRES
e
ACSL5 56 No Yes
SCIN 247 2 Gelsolin No No uORF
d
aAA = Amino acids
bAnk = Ankyrin repeats
cPleck = Pleckstrin
duORF = Upstream open reading frame
eIRES = Internal ribosome entry site
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Page 9 of 14protein function, and we found that OSBPL1A has 31
phosphorylation sites and protein interaction domains that
are unique to the long isoform, indicating a loss of func-
tion for the short isoforms. The long TCF12 variant
encodes 10 glycosylation and Yin-Yang sites along with 27
phosphorylation sites not present in the short isoform.
However, both isoforms contain DNA binding and dimeri-
zation domains, indicating separate functions of the iso-
forms, and not a simple dominant negative function of the
short isoform. Indeed, both the long and short isoform of
the TCF12 have previously been described as having dis-
tinct functions in thymocyte development [31,32]. Deregu-
lation of Tcf12 has recently been causally implicated in
CRC in a DNA transposon based forward genetic screen
in a mouse model. Interestingly, in this study, Tcf12 was
the fourth most commonly mutated gene locus (Apc being
the most commonly mutated gene) [33]. This clearly indi-
cates that TCF12 could have an important effect in CRC
development. In silico predictions for the remaining candi-
date genes indicated diverse functional differences such as
altered protein localization, changes in protein-protein
interaction domains and differences in translational regu-
lation and efficiency.
The selective use of alternative TSSs has been observed
in different cell types, tissue types and developmental
stages [8], however, the mechanism regulating the alterna-
tive TSS usage is often less well described. Aberrant TSS
usage has also been linked to cancer, and in vitro studies
of hypoxia in a CRC cell line revealed hundreds of genes
with altered TSSs [34]. To elaborate on the possible
mechanisms regulating the alternative TSS usage in CRC,
we combined TF binding site enrichment analysis and TF
expression analysis and showed that several TFs were dys-
regulated in tumors along with having enriched binding
sites in the TSS regions. Furthermore, we used cell line
models to demonstrate that abrogation of Wnt signalling
leads to altered TSS usage for OSBPL1A and TRAK1,
showing that the major pathway in CRC development
could be a key regulator of TSS usage.
Conclusions
The use of alternative TSSs is a widespread phenomenon
in human genes, and by using exon array analysis, we
identified nine genes with differential expression of iso-
forms between normal and tumor samples arising from
differential TSS use. The changes observed for CHEK1,
OSBPL1A and TCF12 were confirmed in several other
cancer types indicating that the change in TSS usage is a
general mechanism in cancer biology. The shift in OSB-
PL1A isoform ratio was experimentally shown to be regu-
lated by the Wnt pathway, which is deregulated not only
in CRC, but also in many other cancer types. A TCF12
short variant was found to be de novo synthesized in
colorectal tumors, and TCF12 protein level was shown to
be associated with progression free survival, further under-
lining the potential importance of alternative TSS usage in
cancer development.
Methods
Clinical samples
One hundred and eight colorectal patient biopsies com-
prising 24 adjacent normal mucosa samples, 49 MSS ade-
nomas (16 tubular, 12 tubulovillous and 21 villous), 30
MSS carcinomas (one stage I, 16 stage II and 13 stage III)
and five MSI carcinomas (four stage II and one stage III)
were examined (see Additional file 4 for a summary of
the histopathological characteristics). All carcinomas
were classified according to the WHO/UICC-TNM sta-
ging system. Immediately after surgery or polypectomy,
the biopsies were embedded in Tissue-Tek O.C.T. Com-
pound (Sakura Finetek), snap-frozen in liquid nitrogen
and stored at -80°C. All patients gave informed written
consent, and the study was approved by the Central Den-
mark Region Committee on Biomedical Research Ethics
according to the Helsinki Declaration.
For recurrence free survival analysis, IHC was per-
formed on a human colorectal TMA containing 268
biopsies from stage II adenocarcinomas. The fraction of
patients with recurrence (distant metastasis excluding
carcinosis) was 42 (16%). The median duration of fol-
low-up for the non-recurrence group was 1709 days
(range 1099-1825 days), and for the recurrence group
770 days (range 95-1681). Before progression free survi-
val analysis, 20 biopsies were excluded because the core
was missing or lacked tumor material, leaving 248 sam-
ples for the analysis. A TMA containing 51 stage II ade-
nocarcinomas and 50 normal mucosa samples was used
to assess the expression of TCF12 and OSBPL1A.
RNA preparation and Human Exon 1.0 ST Array labeling
A Hematoxylin and Eosin stained cryostat section from
all samples was used to evaluate tissue composition and
when necessary macroscopic trimming was used to
enrich the fraction of tumor cells to ensure a minimum
of 60% neoplastic cells (median 85% (60%-90%)). Total
RNA was isolated from serial cryo-sections using the
RNeasy Mini elute kit (Qiagen). Quality of the RNA was
evaluated on the 2100 Bioanalyzer (Agilent), the median
RNA Integrity Number (RIN) was 9.1 (6-10), and the
median 28S/18S ribosomal peak ratio was 1.8 (1.1-3.1).
One hundred ng of total RNA was labeled according
to the GeneChip Whole Transcript (WT) Sense Target
Labeling Assay (Affymetrix, Inc., Santa Clara, CA) and
hybridized to Human Exon 1.0 ST Arrays (Affymetrix,
Inc., Santa Clara, CA) overnight. Scanning was per-
formed in an Affymetrix GCS 3000 7G scanner.
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Page 10 of 14Exon array data analysis
Quantile normalization of exon array data and all further
analysis was performed in the GeneSpring GX10 software
(Agilent) using ExonRMA16 with core transcripts (17881
transcripts). For stabilization of variance, 16 was added to
expression values before log2 transformation, which
resulted in a minimum value of four in the log2 trans-
formed dataset. Differential gene expression analysis was
performed on transcript values based on core probe sets
using Benjamini-Hochberg corrected unpaired t-tests.
Alternative TSS analysis was limited to genes in the hg18
Refseq database containing two or more transcription start
sites and at least one protein-coding isoform (2176 genes).
To have probe sets in all exons of these genes, both core
and extended probe sets of the exon array [35] were
included in analysis of alternative TSS. Only genes for
which more than 50% of the probe sets were expressed
above background in at least half of both the normal and
the tumor samples were included in the TSS analysis.
Genes with potential alternative TSS or alternative splicing
were identified using a multivariate ANOVA analysis (spli-
cing ANOVA) and 663 genes had a splicing ANOVA p-
value < 0.05 (Benjamini-Hochberg corrected). More strin-
gent filtration on the p-value (<10
-6, Benjamini-Hochberg
corrected) and the log2 splicing index (SI = probe set
intensity/transcript expression value) SI > 0.5 or SI < -0.5
resulted in 156 candidate genes. To identify genes expres-
sing isoforms with alternative TSSs, the expression data of
the candidate genes were visualized in a genomic context
using the UCSC genome browser [36]. This manual cura-
tion identified nine candidate genes with apparent alterna-
tive TSS usage, which were further analyzed in two
independent validation sample sets, and it was required
that candidate genes were found to be significant in at
least one of the validation sets (splicing ANOVA p-value
(< 0.05) and SI (> 0.5 or SI < -0.5)). The student’st - t e s t
was used when comparing two sample groups, except for
the analysis of paired samples were a paired t-test was
used.
Quantitative real-time reverse-transcription PCR
One μg of total RNA was converted to cDNA using a mix-
ture of oligo(dT) and random nonamer primers and
Superscript II Reverse Transcriptase (Invitrogen). Quanti-
tative real-time reverse-transcription PCR (qRT-PCR) was
performed in triplicates on a 7500 Fast or 7900HT Real-
Time PCR System (Applied Biosystems). See Additional
file 5 for the sequences of the primers used. Normalization
was performed with UBC as previously described [37].
Laser capture microdissection
Laser capture microdissection was performed on cryo-
sections from paired cancer and adjacent normal colon
mucosa biopsies from six patients (two stage II and four
stage III). Briefly, the sections were fixed in 95% EtOH
for 120 sec, followed by 15 sec of staining in Arcturus
Histogene Staining Solution (DFA Instruments), dehy-
drated in 95% EtOH (30 sec) and 100% EtOH (120 sec)
before a final treatment in xylene for 120 sec. After dry-
ing of slides, epithelial and stromal cells were captured
on individual caps using the Veritas 704 apparatus (Arc-
turus). Captured material was incubated with RLT buf-
fer (Qiagen) for 20 minutes at room temperature in the
presence of 30 mM b-mercaptoethanol, and, subse-
quently, RNA was extracted using RNeasy MinElute
spin columns (Qiagen). Five ng RNA was used for
cDNA synthesis using the Ovation PicoSL WTA System
(NuGEN) followed by qRT-PCR as described above.
TMA staining and scoring
Staining of the TMAs was performed with the following
antibodies; Anti-TCF12 (Catalog Number: 14419-1-AP,
ProteinTech) in a 1:250 dilution and anti-OSBPL1A (Cata-
log Number: 18-202-335518, Genway Biotech) in a 1:400
dilution and indirect staining was used as previously
described [38].
The TMAs were scored by two independent investiga-
tors using the VIS software (Visiopharm). The intensity of
the staining was scored within the following categories
(negative, 0; weak, 1; moderate, 2 and strong, 3) and the
fraction of positive cancer cells (negative, 0; less than half,
1; 51-80%, 2 and >80%, 3) was evaluated independently by
two investigators. The agreement between the investiga-
tors was evaluated by Kappa statistics. STATA 9.2 soft-
ware (StataCorp) was used to perform univariate analysis
using the log rank test or the Cox proportional hazards
model, for the Fishers exact test and for generating
Kaplan-Meier plots.
Wnt-pathway model system
The colon cancer cell lines (Ls174T and DLD1) stably
expressing inducible dominant-negative (dn)TCF1 or
d n T C F 4w e r eak i n dg i f tf r o mD r .H a n sC l e v e r s( T h e
Hubrecht Laboratory, The Netherlands), and have pre-
viously been described [39]. b-catenin knockdown was
performed in DLD1 cells by transfecting with 20 nM
siRNA targeting b-catenin (Dharmacon) or 20 nM
scrambled nontargeting siRNA. Transfections were carried
out using Lipofectamine 2000 (Invitrogen). RNeasy (Qia-
gen) was used for RNA extraction and random nonamer
primers were used for cDNA synthesis. qRT-PCR was per-
formed as described above.
Transcription factor binding analysis
For each of the selected genes, 300 bp upstream and
100 bp downstream of the transcription start site were
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Page 11 of 14analyzed for transcription factor binding sites. Using the
TOUCAN2 program [14], the regions were scanned for
known binding domains from the Transfac Public v7 ver-
tebrate database. Domains overrepresented relative to the
Eukaryotic Promoter Database [40] were selected, and
tumor and normal samples were compared.
Additional Human Exon 1.0 ST datasets
The external colon cancer validation dataset was down-
loaded from http://www.affymetrix.com and consisted of
18 paired samples of adenocarcinoma and adjacent normal
tissue [35]. The internal independent colon cancer valida-
tion set consisted of nine adjacent normal biopsies, six tub-
ular adenomas, 13 MSS cancer and 6 MSI cancer samples
and has previously been described [29]. The bladder cancer
dataset consisted of 11 samples of normal epithelium, 12
T1tumors and 12 T2-4 tumors [29]. Five additional data-
sets covering brain gliomas (GSE9385), gastric (GSE13195),
lung (GSE12236), liver (GSE12941) and prostate cancer
(GSE21034) were downloaded from the Gene Expression
Omnibus. The brain glioma dataset contained 26 glioblas-
tomas, 22 oligodendrogliomas and 6 control brain samples
[41]. The gastric cancer dataset consisted of 44 paired sam-
ples of adenocarcinoma and adjacent normal tissue. The
lung cancer dataset consisted of 40 paired normal and lung
adenocarcinomas [42]. The liver cancer dataset contained
20 paired samples of hepatocellular carcinoma and adja-
cent nontumorous liver [43], and the prostate cancer data-
set consisted of 29 normal adjacent benign samples, 131
primary tumors and 19 metastases [44].
Bioinformatics analysis of differentially expressed protein
features and mRNA regulatory elements
First, the peptides corresponding to the unique sequences
of the different isoforms were aligned against the Protein
Data Bank database by PSIBLAST [45]. Then Feature-
Map3D [46], PyMOL (Molecular Graphics System,
Delano, Scientific system, LLC, Palo Alto, CA), and
scripts created for the analysis were used to analyze and
visualize the structures and/or conserved domains. Sec-
ondary structures were predicted by PSIpred [47]. Hydro-
phobicity plots were based on Kyte-Doolittle and Hopp-
Woods scales to predict potential hydrophilic regions
most likely exposed on the protein surface. NetPhos [18]
was used to predict phosphorylation sites. Furthermore,
signal peptide cleavage site prediction was performed
[20] along with prediction of propeptide cleavage sites,
Yin-Yang sites and N-glycosylation and O-glycosylation
sites [48]. Protein functions that potentially change
between alternative isoforms were compared with Prot-
Fun [49]. Regulatory RNA elements in UTRs related to
transcriptional and translational regulation were pre-
dicted by RegRNA [22,50,51].
Additional material
Additional file 1: Expression of TCF12, OSBPL1A and TRAK1 in
paired normal and tumor samples
Additional file 2: qRT-PCR of laser capture microdissected samples
Additional file 3: OSBPL1A and TCF12 isoform expression in
multiple cancer types
Additional file 4: Table with summary of the histopathological
characteristics
Additional file 5: Sequence of primers used for qRT-PCR
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